Literature DB >> 1744453

Diagnosis of pancreatic cancer. Serological markers.

K Satake1.   

Abstract

Many serological markers that are widely used for delecting pancreatic cancer are discussed. Some are good indicators, but others are not. Among them, CA19-9 and SPan-1 radioimmunoassays have a higher sensitivity and specificity. However, these markers are neither tumor-specific nor pancreatic cancer-specific. Accurate understanding of their measurement made it possible to diagnose pancreatic cancer, even when the cancer was small, and to monitor the patients after treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1744453     DOI: 10.1007/bf02925584

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  3 in total

1.  Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.

Authors:  M A Tempero; E Uchida; H Takasaki; D A Burnett; Z Steplewski; P M Pour
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

2.  Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.

Authors:  B C Del Villano; S Brennan; P Brock; C Bucher; V Liu; M McClure; B Rake; S Space; B Westrick; H Schoemaker; V R Zurawski
Journal:  Clin Chem       Date:  1983-03       Impact factor: 8.327

3.  Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.

Authors:  K Satake; G Kanazawa; I Kho; Y Chung; K Umeyama
Journal:  Am J Gastroenterol       Date:  1985-08       Impact factor: 10.864

  3 in total
  2 in total

Review 1.  Advances in biomarker research for pancreatic cancer.

Authors:  Kruttika Bhat; Fengfei Wang; Qingyong Ma; Qinyu Li; Sanku Mallik; Tze-Chen Hsieh; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Production of endothelin-1 and thrombomodulin by human pancreatic cancer cells.

Authors:  T Oikawa; M Kushuhara; S Ishikawa; J Hitomi; A Kono; T Iwanaga; K Yamaguchi
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.